246 related articles for article (PubMed ID: 24812670)
1. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.
Kong G; Wunderlich M; Yang D; Ranheim EA; Young KH; Wang J; Chang YI; Du J; Liu Y; Tey SR; Zhang X; Juckett M; Mattison R; Damnernsawad A; Zhang J; Mulloy JC; Zhang J
J Clin Invest; 2014 Jun; 124(6):2762-73. PubMed ID: 24812670
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.
Zhang J; Ranheim EA; Du J; Liu Y; Wang J; Kong G; Zhang J
J Biol Chem; 2015 Jul; 290(31):19093-103. PubMed ID: 26082490
[TBL] [Abstract][Full Text] [Related]
3. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
[TBL] [Abstract][Full Text] [Related]
4. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Chang T; Krisman K; Theobald EH; Xu J; Akutagawa J; Lauchle JO; Kogan S; Braun BS; Shannon K
J Clin Invest; 2013 Jan; 123(1):335-9. PubMed ID: 23221337
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Akutagawa J; Huang TQ; Epstein I; Chang T; Quirindongo-Crespo M; Cottonham CL; Dail M; Slusher BS; Friedman LS; Sampath D; Braun BS
Leukemia; 2016 Jun; 30(6):1335-43. PubMed ID: 26965285
[TBL] [Abstract][Full Text] [Related]
6. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
[TBL] [Abstract][Full Text] [Related]
7. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
8. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
9. Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M; Della Porta MG; Gallì A; Panini N; Licandro SA; Bello E; Craparotta I; Rosti V; Bonetti E; Tancredi R; Rossi M; Mannarino L; Marchini S; Porcu L; Galmarini CM; Zambelli A; Zecca M; Locatelli F; Cazzola M; Biondi A; Rambaldi A; Allavena P; Erba E; D'Incalci M
Br J Cancer; 2017 Jan; 116(3):335-343. PubMed ID: 28072764
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract][Full Text] [Related]
11. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O
Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879
[TBL] [Abstract][Full Text] [Related]
12. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.
Wang J; Liu Y; Li Z; Du J; Ryu MJ; Taylor PR; Fleming MD; Young KH; Pitot H; Zhang J
Blood; 2010 Dec; 116(26):5991-6002. PubMed ID: 20921338
[TBL] [Abstract][Full Text] [Related]
13. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.
Gritsman K; Yuzugullu H; Von T; Yan H; Clayton L; Fritsch C; Maira SM; Hollingworth G; Choi C; Khandan T; Paktinat M; Okabe RO; Roberts TM; Zhao JJ
J Clin Invest; 2014 Apr; 124(4):1794-809. PubMed ID: 24569456
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo.
Wang T; Li C; Xia C; Dong Y; Yang D; Geng Y; Cai J; Zhang J; Zhang X; Wang J
Am J Transl Res; 2015; 7(10):1963-73. PubMed ID: 26692939
[TBL] [Abstract][Full Text] [Related]
15. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
McCullough KB; Kuhn AK; Patnaik MM
Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
[TBL] [Abstract][Full Text] [Related]
16. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
[TBL] [Abstract][Full Text] [Related]
17. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
Tasian SK; Casas JA; Posocco D; Gandre-Babbe S; Gagne AL; Liang G; Loh ML; Weiss MJ; French DL; Chou ST
Leukemia; 2019 Jan; 33(1):181-190. PubMed ID: 29884903
[TBL] [Abstract][Full Text] [Related]
18. K-RasV14I recapitulates Noonan syndrome in mice.
Hernández-Porras I; Fabbiano S; Schuhmacher AJ; Aicher A; Cañamero M; Cámara JA; Cussó L; Desco M; Heeschen C; Mulero F; Bustelo XR; Guerra C; Barbacid M
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16395-400. PubMed ID: 25359213
[TBL] [Abstract][Full Text] [Related]
19. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
[TBL] [Abstract][Full Text] [Related]
20. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
